title: Factors influencing the prognosis of patients with intrahepatic cholangiocarcinoma.
abstract: OBJECTIVE
  The outcome of surgical treatment of patients with intrahepatic cholangiocarcinoma (ICC) is poor. This study was designed to analyze prognostic factors following surgical treatment for ICC.
  
  
  METHODS
  A structured telephone interview was conducted in 132 patients who were surgically treated for ICC. Fifteen clinical and pathological factors that may influence post-operative survival were analyzed by using Cox proportional hazards model.
  
  
  RESULTS
  The accumulative 1-, 3-, 5-year survival rate of the 132 patients was 51.3%, 21.6%, and 11.8% respectively. The mean survival time in patients with elevated serum carbohydrate antigen (CA) 19-9 at the time of the operation was shorter than in patients with normal serum CA19-9 (9.6 +/- 24.7 vs 16.1 +/- 6 months, P < 0.01). The median survival time in patients with well-differentiated carcinoma was longer than in those with poorly differentiated ICC (23.9 +/- 7.8 vs. 11.2 +/- 5.0 months, P < 0.01). Patients who were treated with hepatectomy and lymph node dissection had a longer survival time than those treated with hepatectomy only (16.0 +/- 5.8 vs 10.2 +/- 3.6 months, P < 0.01). Multivariate analysis showed that mode of surgical treatment, lymph node metastasis, serum level of CA 19-9 and pathological differentiation grade of ICC predicted postoperative survival.
  
  
  CONCLUSIONS
  Hepatectomy with lymph node dissection is associated with an improved survival for patients with ICC. This strategy may be recommended for the surgical treatment of ICC.
authors.affiliation: Department of Hepatobiliary Surgery, Liaocheng People's Hospital and Liaocheng Clinical School of Taishan Medical University, Liaocheng, Shandong, 252000, P.R.China.
authors.forename: Zhi-Heng
authors.initials: ZH
authors.lastname: Liu
authors.forename: Zhong
authors.initials: Z
authors.lastname: Chen
authors.forename: Long-Le
authors.initials: LL
authors.lastname: Ma
authors.forename: Xue-Hua
authors.initials: XH
authors.lastname: Li
authors.forename: Le-Xin
authors.initials: LX
authors.lastname: Wang
mesh_terms: D000328:Adult; D000368:Aged; D001650:Bile Duct Neoplasms / Q000097:blood / Q000473:pathology / Q000601:surgery*; D001653:Bile Ducts, Intrahepatic / Q000473:pathology / Q000601:surgery*; D018395:CA-19-9 Antigen / Q000097:blood; D018281:Cholangiocarcinoma / Q000097:blood / Q000473:pathology / Q000601:surgery*; D005260:Female; D006498:Hepatectomy; D006801:Humans; D008197:Lymph Node Excision; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D016016:Proportional Hazards Models
chemical_list: D018395:CA-19-9 Antigen